Plymouth, MN – According to filings with the U.S. Securities and Exchange Commission, Nuvaira is raising $49,999,997.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Dennis Wahr played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nuvaira

Nuvaira, Inc. is a privately held medical device company that develops minimally invasive products to improve outcomes for patients suffering from obstructive lung diseases by addressing underlying disease pathophysiology. Specifically, the company has developed a novel, catheter-based system to treat overactive airway nerves, a common disease feature of both COPD and asthma, in a procedure called Targeted Lung Denervation (TLD). Nuvaira is headquartered in Minneapolis, Minnesota USA and has more than 70 patents issued and pending worldwide.

To learn more about Nuvaira, visit http://www.nuvaira.com/

Contact:
Dennis Wahr, President and Chief Executive Officer
763-450-2800
dwahr@nuvaira.com
https://www.linkedin.com/in/dennis-wahr-m-d-8b3279a7/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved